Recent Updates
Recently added Catalysts

iBio, Inc.

IBIOFDA catalysts, PDUFA dates & pipeline intelligence
$0.8
▼ -0.05 · -5.55%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IBIO financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.6852W HIGH $3.82
Volume
425.47 K
Value Traded
338.04 K
Short % Float
6.26%
Days to Cover
7.2
+5.09%Week
-2.44%1 Month
-45.51%3 Month
-57.62%6 Month
-100%5 Year
-100%All Time

Cash Data

Unlock IBIO cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
56.44 M
EPS (TTM)
-0.49
P/E Ratio
-
Ent. Value
-20.22 M
Total Shares
70.46 M
Float Shares
64.44 M
Insiders
8.54%
Institutions
60.08%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Pre-clinical data presentation
iBio amylin program (selective amylin receptor agonist)
Cardiometabolic therapeutics
Pre-clinicalPeptidesEndocrine
Unlock every IBIO catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IBIO Catalyst Timeline

Dated clinical, regulatory and corporate events for iBio, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for iBio, Inc.

245Total events
9Upcoming
38Tier-1 (high impact)
2010 to 2028Coverage

Upcoming catalysts 2

T2Oral Presentation
Subscribe to view catalyst details
T2Oral Presentation
Subscribe to view catalyst details

Event history 50

●Poster PresentationIBIO-610Presentation
Poster: Deep, Durable Activin E Suppression by Antibody Blockade Drives Fat-Selective Effects in Obese Non-Human Primates
obesitysource ↗
▲Preclinical PoCIBIO-610Preclinical
IBIO-610 extended 28-week obese NHP data show 2.3% vehicle-adjusted weight reduction and sustained Activin E suppression
obesitysource ↗
●Quarterly UpdateCorporate
iBio reports Q1 fiscal year 2027 financial results and corporate update
▲Preclinical PoCPreclinical
Amylin antibody-peptide fusion shows selective amylin receptor 1/3 activation and reduced food intake in lean rats
obesitysource ↗
▲Additional DataIBIO-610Clinical Data
Additional body-composition data from eight-week obese NHP study of IBIO-610 plus semaglutide
obesitysource ↗
▲Oral PresentationIBIO-610Presentation
Preclinical body composition data for IBIO-610 presented at EASD Annual Meeting
obesitysource ↗
▲Additional DataIBIO-610Clinical Data
Additional analysis of eight-week obese NHP study of IBIO-610 plus semaglutide
obesitysource ↗
▲Preclinical PoCIBIO-610Preclinical
IBIO-610 plus semaglutide NHP body composition data presented at EASD
obesitysource ↗
●Quarterly UpdateCorporate
Reported fiscal year 2026 financial results
◆Management ChangeCorporate
Appointment of Molly Carr, M.D. as Chief Medical Officer
Unlock the full IBIO catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IBIO actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-01IBIO-610 Pre-clinical data readout Pre-clinical
Unlock all IBIO historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 45%
Micro Cap
(rank 326 of 723)
Percentile Rank
Showing 2 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
IBIO-600 BiologicsNCT07487376Overweight , ObesityPhase 1 RECRUITING 32May 1, 2027
IBIO-610 BiologicsNCT07890870Obesity & OverweightPhase 1 NOT YET_RECRUITING 32Jan 1, 2028
Unlock the IBIO pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IBIO program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
IBIO-610 obesity2026-11-162.3%; 9.6%; 16.6%; 10.96%Read MoreiBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific ConferencesRead More
Scroll for more · summaries link to the source press release
Unlock every IBIO trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IBIO insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Stoner ElizabethDirectorGrant/Award 60,000 60,000 held$0.00 05/18/2026
Unlock the full IBIO insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
SILVERARC CAPITAL MANAGEMENT, LLC 0.7 % (16.7 %) 6.32 M 5.36 M 52.17% ( 1.84 M)
Unlock every fund holding IBIO
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IBIO
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see IBIO ownership
Insider and institutional ownership, quarter by quarter.

IBIO Short Interest

Shares sold short, counted twice a month.

6.26%
Short % of Float
of tradable shares sold short
4.0M
Shares Sold Short
+8.0% vs prior count
7.2 High
Days to Cover
trading days of normal volume to buy every short share back
563.7K
Avg Daily Volume
the average used for days to cover
Unlock IBIO short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock IBIO option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IBIO option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IBIO options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IBIO ranks across every disease it competes in

Competitive Position is a premium feature
See how IBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IBIO News

IBIO
Nov 16, 2026
IBIOPhases
▲ +5.9%on this news· ran to +20% by day 1

iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences

iBio presented preclinical data for IBIO-610 at ObesityWeek 2026. The antibody reduced body weight by 2.3% in obese primates. It also lowered fat mass while maintaining lean tissue. The company shared amylin program results showing reduced food intake in rats.

Read more →
IBIO
Nov 10, 2026
IBIOPhases
▲ +5.7%on this news

iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update

iBio reported Q1 fiscal 2027 results with $1.1 million revenue and $76.7 million cash. The company presented preclinical data showing IBIO-610 drove 93% fat loss with semaglutide. iBio completed dosing in the single ascending dose portion of the IBIO-600 Phase 1 trial. Management plans to initiate first-in-human studies for IBIO-610 in early 2027.

Read more →
IBIO
Nov 2, 2026
IBIOConferences/Events

iBio to Participate in Upcoming Investor Conferences

iBio, Inc. announced its participation in several investor conferences in November and December 2026. Key executives, including CEO Martin Brenner and CFO Felipe Duran, will engage in fireside chats and one-on-one meetings. The conferences include the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference.

Read more →
IBIO
Oct 13, 2026
IBIOPhases
▼ -13.4%on this news

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

iBio, Inc. presented promising data from a non-human primate study on IBIO-610, an Activin E antibody, showing enhanced muscle preservation when combined with semaglutide. The study indicated that 93% of weight loss was from fat in subjects receiving both treatments. iBio plans to initiate first-in-human trials in the first half of 2027.

Read more →
IBIO
Sep 1, 2026
IBIOConferences/Events

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

iBio, Inc. will participate in the 21st Annual Wells Fargo Healthcare Conference from September 8-10, 2026, in Boston. CEO Martin Brenner will engage in a fireside chat on September 8, and the event will be livestreamed. Additionally, one-on-one investor meetings will be available with company executives.

Read more →
IBIO
Aug 28, 2026
IBIOPhases

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. reported its fiscal year 2026 financial results, highlighting its transition to a clinical-stage company with the initiation of the Phase 1 trial for IBIO-600. The company also advanced its IBIO-610 program, showing promising preclinical results for obesity treatment. Despite a revenue decrease, iBio secured significant financing to support its clinical pipeline and appointed new leadership to enhance its strategic direction.

Read more →
IBIO
Aug 4, 2026
IBIOGeneral

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

iBio, Inc. has appointed Dr. Molly Carr as Chief Medical Officer, enhancing its clinical leadership. Dr. Carr brings over 30 years of experience in endocrinology and metabolic disease, previously holding senior roles at major biopharmaceutical companies. Her leadership is expected to drive iBio's cardiometabolic pipeline towards late-stage development.

Read more →
IBIO
Jul 1, 2026
IBIOPhases

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

iBio, Inc. reported that a single dose of IBIO-610 achieved up to 98% inhibition of active Activin E in an obese non-human primate study, maintaining suppression for eight weeks. The treatment, particularly when combined with semaglutide, showed significant fat loss while preserving lean mass. Full data will be presented at the upcoming EASD Annual Meeting.

Read more →
IBIO
Jun 2, 2026
IBIOConferences/Events

iBio to Participate in Upcoming Healthcare Investor Conferences

iBio, Inc. will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum. CEO Martin Brenner and CFO Felipe Duran will present and hold one-on-one meetings with investors. These events aim to showcase iBio's innovative therapies for cardiometabolic and obesity-related diseases.

Read more →
IBIO
Jun 2, 2026
IBIOPhases
▼ -6.9%on this newsshared move

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio has initiated its Phase 1 clinical trial for IBIO-600, a long-acting anti-myostatin monoclonal antibody aimed at supporting muscle preservation in adults with obesity. The trial will evaluate the safety and efficacy of IBIO-600, with 32 participants expected to enroll. This marks a significant milestone for iBio as it transitions into a clinical-stage biotechnology company.

Read more →
IBIO
May 12, 2026
IBIOPhases

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. reported its financial results for the third quarter of fiscal year 2026, highlighting significant advancements including regulatory clearance for the phase 1 clinical trial of IBIO-600. The company's strategic pipeline expansion into treating pulmonary hypertension associated with heart failure has also been noted. However, iBio reported no revenue during this quarter and an increase in R&D expenses, reflecting both challenges and ongoing investments in its product development. Additionally, promising preclinical data for IBIO-610 was announced, showing effective reductions in fat mass in studies with non-human primates.

Read more →
IBIO
May 8, 2026
IBIOGeneral

iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

iBio appointed Dr. Elizabeth Stoner to its Board of Directors, marking a significant step in the company's transition to a clinical-stage biotech firm. Dr. Stoner brings over 35 years of experience in research and development, having held leadership roles in several biotech companies. Her expertise in clinical strategy is anticipated to be crucial as iBio advances its therapies for obesity and pulmonary hypertension. The CEO expressed optimism about Dr. Stoner's contributions during this pivotal time for the company.

Read more →
IBIO
Apr 8, 2026
IBIOPhases
▲ +6.2%on this news

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio has received regulatory approval to initiate a Phase 1 clinical trial of IBIO-600, a monoclonal antibody aimed at preserving muscle and improving body composition. The trial will begin dosing participants in the second quarter of 2026, marking a significant milestone for the company as it advances to clinical stages. The study, randomized and placebo-controlled, aims to evaluate safety and pharmacokinetics in overweight and obese adults. Previous studies have shown promising results in terms of muscle preservation and body composition improvements.

Read more →
IBIO
Mar 16, 2026
IBIOConferences/Events

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio, Inc. announced a corporate update call scheduled for March 17, 2026, to discuss its strategic expansion into therapies for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company is developing a bispecific antibody aimed at addressing multiple drivers of the disease. iBio's CEO emphasized the potential of this approach to meet significant unmet medical needs in the cardiometabolic space.

Read more →
IBIO
Mar 9, 2026
IBIOPhases

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio, Inc. has announced promising preclinical data revealing IBIO-610's potential as a first-in-class therapy for fat-selective weight loss in obese non-human primates. The study indicated a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass, achieved while maintaining lean mass. These findings, supported by previously observed effects in rodents, strengthen the case for IBIO-610's continued development targeting obesity and related diseases. The complete analysis of data will be presented at scientific conferences throughout 2026.

Read more →
IBIO
Feb 10, 2026
IBIOGeneral
▼ -5.8%on this news

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. has reported its Q2 fiscal year 2026 financial results, revealing no revenue but securing $26 million in PIPE financing to enhance its pipeline programs. The funding will aid in the advancement of IBIO-610 and IBIO-600 towards human clinical trials and extends the company's cash runway into fiscal year 2028. Additionally, iBio noted increased research and development costs due to escalating operational expenditures. Despite these challenges, the company continues to make progress with new preclinical data and presentations at industry conferences.

Read more →
IBIO
Jan 9, 2026
IBIOGeneral
▲ +14.9%on this news

$26 Million Private Placement

iBio, Inc. announced a $26 million private placement financing agreement with high-quality institutional investors. The proceeds will help advance its preclinical cardiometabolic programs and support other pipeline assets until 2028. The offering is set to close around January 13, 2026, and involves the sale of over 11 million shares at $2.35 each. While the financing is a positive step for iBio, there are risks associated with the inability to sell unregistered shares and potential market fluctuations.

Read more →
IBIO
Nov 12, 2025
IBIOGeneral

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. announced its first fiscal quarter 2026 financial results and provided a corporate update, highlighting a robust cash position bolstered by a public offering that could yield up to $100 million in gross proceeds. The presentation of new non-human primate data for the Activin E antibody, IBIO-610, indicates the potential for infrequent dosing while enhancing patient compliance. These developments are part of iBio's ongoing strategy to create next-generation therapies aimed at obesity and cardiometabolic diseases, confirming their commitment to innovation in drug development.

Read more →
IBIO
Oct 30, 2025
IBIOPhases

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio, Inc. has revealed new preclinical data showing the potential of IBIO-610, an Activin E antibody, in fat-selective weight loss and weight maintenance. The study conducted on non-human primates suggests a human half-life of up to 100 days, indicating that treatment could be administered only twice a year. This extended half-life, combined with a unique mechanism of action, positions IBIO-610 as a potential leading therapy for obesity and cardiometabolic diseases, particularly for patients transitioning off GLP-1 therapies.

Read more →
IBIO
Sep 5, 2025
IBIOGeneral

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio, Inc. reported its financial results for fiscal year 2025, highlighting a transformative year with advancements in its pipeline for cardiometabolic diseases and obesity. The company showcased promising data for its antibody candidates IBIO-610 and IBIO-600, alongside securing additional funding to support ongoing research. Despite an increase in operating losses and R&D expenditures, iBio's successful transition to Nasdaq and strategic corporate developments position it for growth. Overall, the firm remains focused on delivering transformative therapies while enhancing shareholder value.

Read more →

About iBio, Inc.

New York, NY 23 employees ibioinc.com
Headquarters600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
BIOPHARMAWATCH ELITE
Trade the next IBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime